Wstęp
Ta strona zawiera kompleksową analizę znanej historii wykorzystywania informacji poufnych w firmie John L Higgins. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Dokonywanie transakcji w ich firmach w oparciu o określone, niepubliczne informacje jest nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4. Pomimo tych ograniczeń badania akademickie sugerują, że insiderzy – ogólnie rzecz biorąc – mają tendencję do osiągania lepszych wyników na rynku w swoich własnych firmach.
Średnia rentowność handlu
Średnia rentowność handlu to średni zwrot ze wszystkich zakupów na otwartym rynku dokonanych przez osobę mającą dostęp do informacji poufnych w ciągu ostatnich trzech lat. Aby to obliczyć, badamy każdy nieplanowany zakup na otwartym rynku dokonany przez insidera, z wyłączeniem wszystkich transakcji oznaczonych jako część planu handlowego 10b5-1. Następnie obliczamy średnią wydajność tych transakcji w ciągu 3, 6 i 12 miesięcy, uśredniając każdy z tych okresów, aby wygenerować ostateczny wskaźnik wydajności dla każdej transakcji. Na koniec uśredniamy wszystkie wskaźniki wydajności, aby obliczyć wskaźnik wydajności dla insidera. Na tej liście znajdują się wyłącznie insiderzy, którzy dokonali co najmniej trzech transakcji w ciągu ostatnich dwóch lat.
Jeśli rentowność handlu insiderów jest oznaczona notką„nie dotyczy”, oznacza to, że insider albo nie dokonał żadnych zakupów na otwartym rynku w ciągu ostatnich trzech lat, albo transakcje, których dokonał, są zbyt nowe, aby obliczyć wiarygodny wskaźnik wydajności.
Częstotliwość aktualizacji: codziennie
Spółki posiadające zgłoszone stanowiska osób mających dostęp do poufnych informacji
Z dokumentów SEC wynika, że John L Higgins zgłosił udziały lub transakcje w następujących spółkach:
| Papier wartościowy | Nazwa | Najnowsze raporty dotyczące udziałów |
|---|---|---|
| US:OABI / OmniAb, Inc. | Director | 2 942 320 |
| US:TECH / Bio-Techne Corporation | Director | 66 876 |
| US:LGND / Ligand Pharmaceuticals Incorporated | Director | 417 695 |
| US:BCRX / BioCryst Pharmaceuticals, Inc. | Director | 15 000 |
Jak interpretować wykresy
Poniższe wykresy przedstawiają notowania akcji papierów wartościowych po każdej niezaplanowanej transakcji na otwartym rynku dokonanej przez John L Higgins. Nieplanowane transakcje to transakcje, które nie zostały dokonane w ramach planu handlowego 10b5-1. Notowania akcji przedstawiono na wykresie jako skumulowaną procentową zmianę ceny akcji. Na przykład, jeśli 1 stycznia 2019 r. dokonano transakcji poufnej, wykres pokaże dzienną procentową zmianę papieru wartościowego do dnia dzisiejszego. Jeżeli cena akcji wzrosłaby w tym czasie z 10 do 15 dolarów, skumulowana procentowa zmiana ceny akcji wyniosłaby 50%. Zmiana ceny z 10$ na 20$ będzie wynosić 100%, a zmiana ceny z 10$ na 5$ będzie wynosić -50%.
Ostatecznie staramy się określić, jak blisko transakcje insiderów korelują z nadmiernymi zwrotami (dodatnimi lub ujemnymi) z ceny akcji, aby sprawdzić, czy insider dostosowuje swoje transakcje w taki sposób, aby czerpać korzyści z informacji poufnych. Rozważmy sytuację, w której zrobił to ktoś z wewnątrz. W tej sytuacji oczekiwalibyśmy albo (a) dodatnich zwrotów po zakupach, albo (b) ujemnych zwrotów po sprzedaży. W przypadku (a) wykres ZAKUPU pokazywałby serię krzywych nachylonych w górę, wskazujących dodatnie zwroty po każdej transakcji zakupu. W przypadku (b) wykres SPRZEDAŻ pokazywałby serię krzywych o nachyleniu w dół, wskazujących ujemne zwroty po każdej transakcji sprzedaży.
Samo to jednak nie wystarczy, aby wyciągnąć wnioski. Gdyby np. cena akcji spółki przez wiele lat rosła niecyklicznie, to spodziewalibyśmy się, że wszystkie wykresy po zakupie będą wykazywały tendencję wzrostową. Podobnie niecykliczne spadki na przestrzeni wielu lat spowodowałyby spadek linii na wykresie po transakcjach. Żaden z tych wykresów nie sugeruje wykorzystywania informacji poufnych.
Najsilniejszym wskaźnikiem byłaby sytuacja, gdy cena akcji miała charakter wyjątkowo cykliczny, a na wykresie KUPNO występowały zarówno pozytywne sygnały na wykresie KUPNA, jak i negatywne na wykresie SPRZEDAŻY. Sytuacja ta wysoce sugerowałaby osobę mającą dostęp do informacji poufnych, która wykorzystywała transakcje w celu uzyskania korzyści finansowej.
Zakupy insidera BCRX / BioCryst Pharmaceuticals, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w BCRX / BioCryst Pharmaceuticals, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera BCRX / BioCryst Pharmaceuticals, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w BCRX / BioCryst Pharmaceuticals, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Historia handlu insiderów
Ta tabela przedstawia pełną listę transakcji insiderów dokonanych przez firmę John L Higgins ujawnioną Komisji Papierów Wartościowych (SEC).
| Data pliku | Data trans | Formularz | Ticker | Bezpieczeństwo | Kod | Akcje | Pozostałe akcje | Zmiana procent |
Cena udziału |
Wartość trans |
Pozostała Wartość |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 172 | 2 942 320 | 0,45 | ||||
| 2025-11-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 41 038 | 2 929 148 | 1,42 | 1,38 | 56 632 | 4 042 224 | |
| 2025-11-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 36 223 | 2 888 110 | 1,27 | 1,41 | 51 074 | 4 072 235 | |
| 2025-11-03 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 640 | 66 876 | 2,51 | ||||
| 2025-08-11 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 040 | 65 236 | 8,37 | 21,84 | 110 074 | 1 424 754 | |
| 2025-06-18 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 20 000 | 2 851 887 | 0,71 | ||||
| 2025-05-13 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 65 000 | 2 831 887 | 2,35 | 1,44 | 93 600 | 4 077 917 | |
| 2025-05-05 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 12 000 | 60 196 | 24,90 | 21,84 | 262 080 | 1 314 681 | |
| 2025-03-21 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 4 000 | 2 766 887 | 0,14 | 2,28 | 9 120 | 6 308 502 | |
| 2025-03-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 125 750 | 2 762 887 | 4,77 | 2,35 | 295 512 | 6 492 784 | |
| 2025-01-30 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 172 | 2 637 137 | 0,50 | ||||
| 2024-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 462 | 48 196 | 3,13 | ||||
| 2024-09-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
F - Taxes | -1 874 | 46 734 | -3,86 | 73,20 | -137 177 | 3 420 929 | |
| 2024-09-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 6 000 | 48 608 | 14,08 | 22,95 | 137 700 | 1 115 554 | |
| 2024-07-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 6 000 | 42 608 | 16,39 | 22,95 | 137 700 | 977 854 | |
| 2024-06-21 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 20 000 | 2 623 965 | 0,77 | ||||
| 2024-05-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -4 000 | 36 608 | -9,85 | 83,84 | -335 377 | 3 069 372 | |
| 2024-05-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 4 000 | 40 608 | 10,93 | 22,95 | 91 800 | 931 954 | |
| 2024-04-23 |
|
4/A | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 2 427 861 | 2 603 965 | 1 378,65 | ||||
| 2024-01-31 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 173 | 2 352 625 | 0,56 | ||||
| 2023-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 625 | 36 608 | 4,65 | ||||
| 2023-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | 57 803 | 2 339 452 | 2,53 | 3,23 | 186 704 | 7 556 430 | |
| 2023-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | 25 914 | 2 397 255 | 1,09 | 3,66 | 94 845 | 8 773 953 | |
| 2023-05-25 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | -9 000 | 2 462 686 | -0,36 | 4,05 | -36 450 | 9 973 878 | |
| 2023-05-25 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 9 000 | 2 471 686 | 0,37 | 3,68 | 33 120 | 9 095 804 | |
| 2023-05-23 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | -1 000 | 2 462 686 | -0,04 | 4,05 | -4 050 | 9 973 878 | |
| 2023-05-23 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 1 000 | 2 463 686 | 0,04 | 3,68 | 3 680 | 9 066 364 | |
| 2023-05-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | -50 000 | 2 462 686 | -1,99 | 3,89 | -194 500 | 9 579 849 | |
| 2023-05-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 50 000 | 2 512 686 | 2,03 | 3,68 | 184 000 | 9 246 684 | |
| 2023-05-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
F - Taxes | -4 377 | 34 983 | -11,12 | 79,88 | -349 635 | 2 794 442 | |
| 2023-05-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 16 000 | 39 360 | 68,49 | 21,85 | 349 600 | 860 016 | |
| 2023-02-01 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 39 517 | 2 462 686 | 1,63 | ||||
| 2022-12-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -5 289 | 417 695 | -1,25 | 66,29 | -350 608 | 27 689 002 | |
| 2022-12-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10 000 | 422 984 | -2,31 | 61,87 | -618 657 | 26 168 201 |
| 2022-12-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -3 944 | 432 984 | -0,90 | 64,80 | -255 571 | 28 057 363 | |
| 2022-12-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 000 | 436 928 | 4,80 | 12,78 | 255 600 | 5 583 940 | |
| 2022-12-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -9 803 | 416 928 | -2,30 | 72,90 | -714 639 | 30 394 051 | |
| 2022-11-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 426 731 | 2,40 | 12,78 | 127 800 | 5 453 622 | |
| 2022-11-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10 000 | 416 731 | -2,34 | 78,32 | -783 173 | 32 637 247 |
| 2022-11-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 45 922 | 424 731 | 12,12 | ||||
| 2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 246 648 | 2 423 169 | 11,33 | 2,52 | 621 553 | 6 106 386 | |
| 2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 2 176 521 | 2 176 521 | |||||
| 2022-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 338 | 5 840 | 6,14 | ||||
| 2022-09-22 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -1 000 | 366 180 | -0,27 | 88,06 | -88 060 | 32 245 811 | |
| 2022-09-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -3 000 | 364 180 | -0,82 | 89,35 | -268 050 | 32 539 483 | |
| 2022-09-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -2 000 | 367 180 | -0,54 | 90,00 | -180 000 | 33 046 200 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -8 | 5 502 | -0,15 | 380,71 | -3 046 | 2 094 666 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -504 | 5 510 | -8,38 | 385,47 | -194 277 | 2 123 936 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -992 | 6 014 | -14,16 | 380,15 | -377 112 | 2 286 240 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -100 | 7 006 | -1,41 | 374,90 | -37 490 | 2 626 514 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -900 | 7 106 | -11,24 | 373,99 | -336 593 | 2 657 586 | |
| 2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 3 400 | 8 006 | 73,82 | 66,90 | 227 460 | 535 601 | |
| 2022-07-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 164 | 369 180 | 0,04 | 75,84 | 12 437 | 27 997 504 | |
| 2022-06-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 20 423 | 369 016 | 5,86 | ||||
| 2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -600 | 4 606 | -11,53 | 366,09 | -219 654 | 1 686 211 | |
| 2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 600 | 5 206 | 13,03 | 66,90 | 40 140 | 348 281 | |
| 2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -1 000 | 4 606 | -17,84 | 364,31 | -364 310 | 1 678 012 | |
| 2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 1 000 | 5 606 | 21,71 | 66,90 | 66 900 | 375 041 | |
| 2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
S - Sale | 429 159,38 | ||||||
| 2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -8 000 | 57 616 | -12,19 | ||||
| 2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 000 | 348 593 | 2,35 | 21,92 | 175 360 | 7 641 159 | |
| 2022-05-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 76 478 | 76 478 | |||||
| 2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 916 | 340 593 | -0,56 | 123,68 | -236 971 | 42 124 542 | |
| 2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 061 | 342 509 | -0,60 | 123,68 | -254 904 | 42 361 513 | |
| 2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 946 | 344 570 | -0,56 | 123,68 | -240 681 | 42 616 418 | |
| 2022-02-07 |
|
5 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
G - Gift | -2 502 | 332 593 | -0,75 | ||||
| 2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -6 183 | 349 018 | -1,74 | 113,68 | -702 883 | 39 676 366 | |
| 2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -3 060 | 355 201 | -0,85 | 113,68 | -347 861 | 40 379 250 | |
| 2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 13 560 | 358 261 | 3,93 | ||||
| 2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 606 | 344 701 | 2,87 | ||||
| 2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -3 000 | 335 095 | -0,89 | 160,50 | -481 500 | 53 782 748 | |
| 2021-11-01 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 633 | 633 | |||||
| 2021-11-01 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 194 | 4 606 | 4,40 | ||||
| 2021-07-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 247 | 338 095 | 0,07 | 85,91 | 21 220 | 29 045 572 | |
| 2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 061 | 337 848 | -0,61 | 172,46 | -355 440 | 58 265 266 | |
| 2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 947 | 339 909 | -0,57 | 172,46 | -335 780 | 58 620 706 | |
| 2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 204 | 341 856 | -0,35 | 172,46 | -207 642 | 58 956 486 | |
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -54 666 | 14 334 | -79,23 | |||
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -60 000 | 0 | -100,00 | ||||
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 970 | 343 060 | -0,86 | 203,03 | -602 999 | 69 651 472 | |
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 60 000 | 346 030 | 20,98 | 10,05 | 603 000 | 3 477 602 | |
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -54 666 | 286 030 | -16,05 | 203,40 | -11 119 239 | 58 179 417 | |
| 2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 54 666 | 340 696 | 19,11 | 14,47 | 791 017 | 4 929 871 |
| 2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 25 113 | 25 113 | |||||
| 2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 608 | 286 030 | 4,61 | ||||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -30 000 | 65 616 | -31,38 | ||||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -40 000 | 69 000 | -36,70 | |||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 30 000 | 273 422 | 12,32 | 21,92 | 657 600 | 5 993 410 | |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -40 000 | 243 422 | -14,11 | 182,00 | -7 280 000 | 44 302 804 |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 40 000 | 283 422 | 16,43 | 14,47 | 578 800 | 4 101 116 |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -50 000 | 109 000 | -31,45 | |||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -4 596 | 243 422 | -1,85 | 156,01 | -717 022 | 37 976 266 | |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 607 | 248 018 | 4,03 | ||||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 845 | 238 411 | -1,18 | 156,01 | -443 848 | 37 194 500 | |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 946 | 241 256 | 2,53 | ||||
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -50 000 | 235 310 | -17,52 | 159,00 | -7 950 000 | 37 414 290 |
| 2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 50 000 | 285 310 | 21,25 | 14,47 | 723 500 | 4 128 436 |
| 2021-01-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 223 | 235 310 | 0,09 | 84,53 | 18 851 | 19 891 343 | |
| 2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -14 657 | 60 000 | -19,63 | ||||
| 2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 683 | 235 087 | -0,71 | 87,52 | -147 296 | 20 574 814 | |
| 2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 657 | 236 770 | 6,60 | 10,05 | 147 303 | 2 379 538 | |
| 2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -20 000 | 74 657 | -21,13 | ||||
| 2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 458 | 222 113 | -1,09 | 81,77 | -200 991 | 18 162 180 | |
| 2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 000 | 224 571 | 9,78 | 10,05 | 201 000 | 2 256 939 | |
| 2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
M - Exercise | -5 000 | 0 | -100,00 | ||||
| 2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -3 100 | 4 412 | -41,27 | 301,06 | -933 301 | 1 328 297 | |
| 2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -450 | 7 512 | -5,65 | 299,84 | -134 928 | 2 252 392 | |
| 2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -1 450 | 7 962 | -15,41 | 298,98 | -433 516 | 2 380 451 | |
| 2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 9 412 | 113,33 | 70,35 | 351 750 | 662 134 | |
| 2020-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
A - Award | 1 507 | 1 507 | |||||
| 2020-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 391 | 4 412 | 9,72 | ||||
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | -1 165 | 54 226 | -2,10 | ||||
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | -1 373 | 93 627 | -1,45 | ||||
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | -1 777 | 54 421 | -3,16 | ||||
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 373 | 204 571 | 0,68 | 74,42 | 102 179 | 15 224 174 | |
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 777 | 203 198 | 0,88 | 56,26 | 99 974 | 11 431 919 | |
| 2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 165 | 201 421 | 0,58 | 85,79 | 99 945 | 17 279 908 | |
| 2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 310 | 133 982 | -0,97 | 120,86 | -158 327 | 16 193 065 | |
| 2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 689 | 135 292 | -1,23 | 120,86 | -204 133 | 16 351 391 | |
| 2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 918 | 136 981 | -1,38 | 120,86 | -231 809 | 16 555 524 | |
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 117 | 205 173 | -1,02 | 97,23 | -205 836 | 19 948 971 | |
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 310 | 207 290 | -0,63 | 97,23 | -127 371 | 20 154 807 | |
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 689 | 208 600 | -0,80 | 97,23 | -164 221 | 20 282 178 | |
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -48 125 | 0 | -100,00 | ||||
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 60 886 | 60 886 | |||||
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 13 559 | 210 289 | 6,89 | ||||
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -5 009 | 196 730 | -2,48 | 95,68 | -479 261 | 18 823 126 | |
| 2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 48 125 | 201 739 | 31,33 | 9,96 | 479 325 | 2 009 320 | |
| 2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
M - Exercise | -5 000 | 0 | -100,00 | ||||
| 2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -5 000 | 4 021 | -55,43 | 205,23 | -1 026 132 | 825 216 | |
| 2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 9 021 | 124,35 | 61,46 | 307 300 | 554 431 | |
| 2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 948 | 153 614 | -1,88 | 105,87 | -312 105 | 16 263 114 | |
| 2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 946 | 156 562 | 3,95 | ||||
| 2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -3 801 | 150 616 | -2,46 | 105,87 | -402 412 | 15 945 716 | |
| 2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 668 | 154 417 | 5,23 | ||||
| 2019-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 2 011 | 2 011 | |||||
| 2019-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 495 | 4 021 | 14,04 | ||||
| 2019-09-24 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
P - Purchase | 988 468,75 | ||||||
| 2019-09-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
P - Purchase | 841 250,00 | ||||||
| 2019-07-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 850 | 146 749 | 1,28 | 95,45 | 176 582 | 14 007 192 | |
| 2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Options (Right to buy) |
M - Exercise | -5 000 | 0 | -100,00 | ||||
| 2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -5 000 | 3 526 | -58,64 | 203,67 | -1 018 346 | 718 137 | |
| 2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 8 526 | 141,80 | 63,03 | 315 150 | 537 394 | |
| 2019-05-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 144 899 | 0,69 | 108,20 | 108 202 | 15 678 362 | |
| 2019-05-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 500 | 143 899 | 1,77 | 113,50 | 283 750 | 16 332 536 | |
| 2019-03-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 500 | 141 399 | 1,80 | 114,29 | 285 725 | 16 160 492 | |
| 2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 58 596 | 58 596 | |||||
| 2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 809 | 138 899 | 10,16 | ||||
| 2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -3 168 | 126 090 | -2,45 | 111,78 | -354 119 | 14 094 340 | |
| 2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 390 | 129 258 | 5,20 | ||||
| 2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -3 597 | 122 868 | -2,84 | 111,78 | -402 073 | 13 734 185 | |
| 2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 256 | 126 465 | 6,09 | ||||
| 2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -4 000 | 0 | -100,00 | ||||
| 2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -29 790 | 0 | -100,00 | ||||
| 2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 29 790 | 119 209 | 33,32 | 16,14 | 480 811 | 1 924 033 | |
| 2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 000 | 89 419 | 4,68 | 16,14 | 64 560 | 1 443 223 | |
| 2018-10-29 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Options (Right to buy) |
A - Award | 1 898 | 1 898 | |||||
| 2018-10-29 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 514 | 3 526 | 17,07 | ||||
| 2018-08-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -3 500 | 85 419 | -3,94 | 258,25 | -903 875 | 22 059 457 | |
| 2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
M - Exercise | -10 000 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -10 000 | 3 012 | -76,85 | 187,92 | -1 879 173 | 566 007 | |
| 2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 10 000 | 13 012 | 332,01 | 61,08 | 610 800 | 794 773 | |
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -12 993 | 159 000 | -7,55 | |||
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12 993 | 88 919 | -12,75 | 243,00 | -3 157 299 | 21 607 317 |
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 993 | 101 912 | 14,61 | 14,47 | 188 009 | 1 474 667 |
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3 007 | 171 993 | -1,72 | |||
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -21 507 | 88 919 | -19,48 | 241,33 | -5 190 261 | 21 458 724 |
| 2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 3 007 | 110 426 | 2,80 | 14,47 | 43 511 | 1 597 864 |
| 2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | -12 405 | 29 790 | -29,40 | |||
| 2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12 405 | 107 419 | -10,35 | 179,97 | -2 232 491 | 19 331 875 |
| 2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 405 | 119 824 | 11,55 | 16,14 | 200 217 | 1 933 959 |
| 2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 982 | 107 419 | -2,70 | 165,87 | -494 624 | 17 817 590 | |
| 2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 015 | 110 401 | 5,76 | ||||
| 2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 41 392 | 41 392 | |||||
| 2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 928 | 104 386 | 8,22 | ||||
| 2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 689 | 96 458 | -1,72 | 157,18 | -265 477 | 15 161 268 | |
| 2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 918 | 98 147 | -1,92 | 157,18 | -301 471 | 15 426 745 | |
| 2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 635 | 100 065 | -2,57 | 157,18 | -414 169 | 15 728 217 | |
| 2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9 000 | 102 700 | -8,06 | 157,03 | -1 413 279 | 16 127 084 |
| 2018-01-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -22 500 | 111 700 | -16,77 | 165,00 | -3 712 500 | 18 430 500 |
| 2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | -16 249 | 42 195 | -27,80 | |||
| 2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11 850 | 134 200 | -8,11 | 151,92 | -1 800 307 | 20 388 281 |
| 2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16 249 | 146 050 | -10,01 | 155,00 | -2 518 595 | 22 637 750 |
| 2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 16 249 | 162 299 | 11,13 | 16,14 | 262 259 | 2 619 506 |
| 2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -5 199 | 146 050 | -3,44 | 138,66 | -720 893 | 20 251 293 | |
| 2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 965 | 151 249 | 7,05 | ||||
| 2017-11-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -2 258 | 141 284 | -1,57 | 140,34 | -316 888 | 19 827 797 | |
| 2017-11-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -5 269 | 143 542 | -3,54 | 142,53 | -750 991 | 20 459 041 | |
| 2017-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 3 125 | 3 125 | |||||
| 2017-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 739 | 3 012 | 32,51 | ||||
| 2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -11 384 | 0 | -100,00 | ||||
| 2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 744 | 148 811 | -1,16 | 143,04 | -249 462 | 21 285 925 | |
| 2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 11 384 | 150 555 | 8,18 | 21,92 | 249 537 | 3 300 166 | |
| 2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -5 000 | 0 | -100,00 | ||||
| 2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5 000 | 139 171 | -3,47 | 130,00 | -650 000 | 18 092 230 |
| 2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 000 | 144 171 | 3,59 | 21,00 | 105 000 | 3 027 591 |
| 2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | -5 483 | 5 000 | -52,30 | |||
| 2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5 483 | 139 171 | -3,79 | 125,00 | -685 375 | 17 396 375 |
| 2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 483 | 144 654 | 3,94 | 21,00 | 115 143 | 3 037 734 |
| 2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | -4 666 | 0 | -100,00 | |||
| 2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4 666 | 139 171 | -3,24 | 120,00 | -559 920 | 16 700 520 |
| 2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 4 666 | 143 837 | 3,35 | 21,00 | 97 986 | 3 020 577 |
| 2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 4 666 | 4 666 | |||||
| 2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | -12 000 | 10 483 | -53,37 | |||
| 2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12 000 | 139 171 | -7,94 | 114,87 | -1 378 440 | 15 986 573 |
| 2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 000 | 151 171 | 8,62 | 21,00 | 252 000 | 3 174 591 |
| 2017-03-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4 000 | 139 171 | -2,79 | 109,10 | -436 400 | 15 183 556 |
| 2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -15 675 | 0 | -100,00 | ||||
| 2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1 473 | 143 171 | -1,02 | 106,92 | -157 493 | 15 307 843 | |
| 2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 15 675 | 144 644 | 12,15 | 10,05 | 157 534 | 1 453 672 | |
| 2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -4 000 | 128 969 | -3,01 | 107,06 | -428 240 | 13 807 421 | |
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 43 646 | 43 646 | |||||
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 10 224 | 132 969 | 8,33 | ||||
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -4 783 | 122 745 | -3,75 | 100,38 | -480 118 | 12 321 143 | |
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 168 | 127 528 | 7,75 | ||||
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 019 | 118 360 | -1,68 | 104,28 | -210 541 | 12 342 581 | |
| 2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 285 | 120 379 | -1,86 | 104,28 | -238 280 | 12 553 122 | |
| 2016-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 3 985 | 3 985 | |||||
| 2016-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 914 | 2 273 | 67,26 | ||||
| 2016-09-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -3 000 | 122 664 | -2,39 | 117,34 | -352 020 | 14 393 394 | |
| 2016-09-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | -1 700 | 1 359 | -55,57 | 109,83 | -186 716 | 149 263 | |
| 2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -6 000 | 22 483 | -21,07 | ||||
| 2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 000 | 125 664 | 5,01 | 21,00 | 126 000 | 2 638 944 | |
| 2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -556 | 119 664 | -0,46 | 102,97 | -57 251 | 12 321 802 | |
| 2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -10 277 | 120 220 | -7,88 | 102,44 | -1 052 776 | 12 315 337 | |
| 2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2 492 | 130 497 | -1,87 | 85,97 | -214 237 | 11 218 827 | |
| 2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 55 391 | 55 391 | |||||
| 2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 11 611 | 132 989 | 9,57 | ||||
| 2015-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
A - Award | 4 260 | 4 260 | |||||
| 2015-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 059 | 3 059 | 52,95 | ||||
| 2015-08-07 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -4 666 | 121 378 | -3,70 | 110,79 | -516 946 | 13 447 469 | |
| 2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -500 | 126 044 | -0,40 | 95,06 | -47 530 | 11 981 743 | |
| 2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -3 300 | 126 544 | -2,54 | 93,21 | -307 593 | 11 795 166 | |
| 2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -6 200 | 129 844 | -4,56 | 92,53 | -573 686 | 12 014 465 | |
| 2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 56 198 | 56 198 | 56,26 | 3 161 699 | 3 161 699 | ||
| 2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 15 945 | 136 044 | 13,28 | ||||
| 2014-11-03 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
| 2014-11-03 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 000 | 2 000 | 100,00 | ||||
| 2014-08-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 120 099 | 0,84 | 54,97 | 54 970 | 6 601 842 | |
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -16 875 | 48 125 | -25,96 | |||
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 95 000 | 11,76 | 74,42 | 744 200 | 7 069 900 | |
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 95 000 | 11,76 | 74,42 | 744 200 | 7 069 900 | |
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 75 000 | 75 000 | 74,42 | 5 581 500 | 5 581 500 | ||
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 8 000 | 119 099 | 7,20 | ||||
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16 875 | 111 099 | -13,19 | 75,00 | -1 265 625 | 8 332 425 |
| 2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 16 875 | 127 974 | 15,19 | 9,96 | 168 075 | 1 274 621 | |
| 2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -9 000 | 28 483 | -24,01 | 21,00 | -189 000 | 598 143 | |
| 2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 9 000 | 111 099 | 8,81 | 21,00 | 189 000 | 2 333 079 | |
| 2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15 000 | 102 099 | -12,81 | 64,00 | -960 000 | 6 534 336 |
| 2013-11-04 |
|
4 | TECH |
TECHNE CORP /MN/
Stock Option |
A - Award | 4 000 | 4 000 | |||||
| 2013-11-04 |
|
4 | TECH |
TECHNE CORP /MN/
Common Stock |
A - Award | 1 000 | 1 000 | |||||
| 2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -5 850 | 37 483 | -13,50 | ||||
| 2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -4 668 | 15 675 | -22,95 | ||||
| 2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 668 | 117 099 | 4,15 | 10,05 | 46 913 | 1 176 845 | |
| 2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 850 | 112 431 | 5,49 | 21,00 | 122 850 | 2 361 051 | |
| 2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10 000 | 106 581 | -8,58 | 55,00 | -550 000 | 5 861 955 |
| 2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | -6 556 | 58 444 | -10,09 | ||||
| 2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 556 | 116 581 | 5,96 | 16,14 | 105 814 | 1 881 617 | |
| 2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -10 000 | 110 025 | -8,33 | 42,85 | -428 500 | 4 714 571 | |
| 2013-06-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 14 334 | 14 334 | 32,00 | 458 688 | 458 688 | ||
| 2013-06-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 000 | 120 025 | 11,11 | ||||
| 2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 160 666 | 160 666 | 14,47 | 2 324 837 | 2 324 837 | ||
| 2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 000 | 95 275 | 6,72 | ||||
| 2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 95 616 | 95 616 | 21,92 | 2 095 903 | 2 095 903 | ||
| 2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
A - Award | 11 384 | 11 384 | 21,92 | 249 537 | 249 537 | ||
| 2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 8 000 | 120 025 | 7,14 | ||||
| 2012-12-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 000 | 112 025 | 1,82 | 18,03 | 36 060 | 2 019 811 | |
| 2012-10-26 |
|
4 | TECH |
TECHNE CORP /MN/
Stock Option |
A - Award | 5 000 | 5 000 | |||||
| 2012-08-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 500 | 110 025 | 0,46 | 16,39 | 8 195 | 1 803 310 | |
| 2012-07-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 250 | 109 525 | 1,15 | 10,12 | 12 654 | 1 108 776 | |
| 2012-05-25 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 15 000 | 15 000 | |||||
| 2012-05-08 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 108 275 | 0,93 | 12,04 | 12 040 | 1 303 631 | |
| 2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 175 000 | 175 000 | 14,47 | 2 532 250 | 2 532 250 | ||
| 2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 18 000 | 107 275 | 20,16 | ||||
| 2012-01-06 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 210 | 89 275 | 0,24 | 10,09 | 2 119 | 900 740 | |
| 2004-05-18 | 3/A | BCRX |
BIOCRYST PHARMACEUTICALS INC
None |
0 |
